Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRECOSE vs GLYSET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in patients with impaired glucose tolerance
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
Terminal elimination half-life is approximately 2 hours for the parent drug, but clinical effect persists due to prolonged binding to intestinal alpha-glucosidases.
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 m L/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease).
Not extensively metabolized; primarily excreted unchanged in the urine as active drug. Small fraction undergoes intestinal metabolism by digestive enzymes.
Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug).
Primarily excreted in feces (about 85%) as unchanged drug and metabolites, with less than 2% excreted renally as active metabolites.
Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%).
Low protein binding, approximately 5%, primarily to albumin.
Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins.
Volume of distribution is approximately 0.3 L/kg, indicating minimal distribution into tissues and predominantly confined to extracellular fluid.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding.
Oral bioavailability is low, approximately 2%, due to local action in the gastrointestinal tract and minimal systemic absorption.
Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut.
No dose adjustment recommended for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <25 m L/min/1.73 m²).
Contraindicated if GFR < 25 m L/min/1.73 m². No adjustment needed for GFR ≥ 25 m L/min/1.73 m².
No dose adjustment recommended for mild hepatic impairment. Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); avoid use.
No specific guidelines; use caution in Child-Pugh class B or C due to limited data.
Not recommended for pediatric patients (safety and efficacy not established).
Not recommended for pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment required; monitor renal function due to age-related decline. Start at low end of dosing range (25 mg three times daily).
Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline.
None.
None
Hypoglycemia: Acarbose does not cause hypoglycemia when used alone, but may increase risk when combined with sulfonylureas or insulin. Hypoglycemic episodes should be treated with glucose (dextrose), not sucrose.,Hepatic injury: Rare cases of acute hepatitis, jaundice, and fulminant hepatic failure; monitor liver function tests.,Renal impairment: Contraindicated in patients with Cr Cl <25 m L/min.,Gastrointestinal effects: Frequently causes flatulence, diarrhea, and abdominal discomfort due to undigested carbohydrates; these effects may diminish with continued use.
Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose),Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon,Hepatotoxicity (rare, monitor liver enzymes),May cause loss of glycemic control if used with intestinal disorders
Hypersensitivity to acarbose or any component,Diabetic ketoacidosis,Cirrhosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction or predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Conditions that may deteriorate as a result of increased intestinal gas formation (e.g., Roemheld syndrome),Severe renal impairment (Cr Cl <25 m L/min)
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction,Predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Cirrhosis,Hypersensitivity to miglitol
Avoid sucrose and table sugar as they may worsen GI side effects. Dietary carbohydrates increase efficacy but also GI side effects. Precose alone does not cause hypoglycemia; however, if used with insulin or sulfonylureas, hypoglycemia must be treated with glucose (dextrose) because absorption of complex sugars and sucrose is inhibited.
Avoid high-sucrose or fructose-containing foods and drinks as GLYSET inhibits the digestion of sucrose, leading to increased fermentation and gastrointestinal distress. Complex carbohydrates (starches) are affected; simple sugars like glucose are not.
Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.
Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.
Unknown if excreted in human milk. Caution advised. M/P ratio not established.
Excreted in human milk; M/P ratio unknown. Caution in nursing mothers due to potential for GI effects in infants.
No dose adjustment recommended; monitor glucose control closely as pharmacokinetics may change; insulin often preferred.
No dose adjustment recommended based on pharmacokinetic data; monitor glycemic control closely and adjust as needed.
Precose (acarbose) is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is most effective for postprandial hyperglycemia. Must be taken with the first bite of each main meal. Avoid use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Can cause elevated liver enzymes; monitor LFTs every 3 months during first year. Hypoglycemia from other agents should be treated with glucose (not sucrose) because sucrase is inhibited.
GLYSET (miglitol) is an alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial hyperglycemia. It is not effective for fasting hyperglycemia and should not be used as monotherapy for type 1 diabetes or DKA. Monitor liver function tests; rare hepatotoxicity reported. Avoid in patients with inflammatory bowel disease or intestinal obstruction.
Take this medication with the first bite of each main meal.,If you experience low blood sugar, treat it with glucose tablets or milk, not fruit juice or regular soda.,Common side effects include flatulence, diarrhea, and abdominal pain, which often decrease with time.,Do not take this drug if you have severe kidney problems or certain bowel diseases.,Report any signs of liver problems (yellow skin/eyes, dark urine, abdominal pain) immediately.
Take with the first bite of each main meal to delay carbohydrate absorption.,Common side effects include flatulence, diarrhea, and abdominal discomfort, which often improve over time.,If hypoglycemia occurs, use glucose tablets or milk, not sucrose or fruit juice, as GLYSET prevents sucrose breakdown.,Monitor blood glucose regularly, especially when starting or changing dose.,Do not skip meals; take medication exactly as prescribed.
No interactions on record
No interactions on record
Common clinical questions about PRECOSE vs GLYSET, answered by our medical review team.
PRECOSE is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.. GLYSET is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRECOSE and GLYSET depend on the specific clinical indication. These are both Alpha-Glucosidase Inhibitor Antidiabetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRECOSE is: Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.. The standard adult dose of GLYSET is: 50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRECOSE and GLYSET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRECOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.. GLYSET is classified as Category C. Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.